Targeting checkpoint kinase 1 in cancer therapeutics

Archie N. Tse, Richard Carvajal, Gary K. Schwartz

Research output: Contribution to journalReview articlepeer-review

144 Scopus citations


Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Our knowledge of the biochemical nature of checkpoint regulation during an unperturbed cell cycle and following DNA damage has expanded tremendously over the past decade. We now know that dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumor progression, and most agents used for cancer therapy, such as cytotoxic chemotherapy and ionizing radiation, also activate cell cycle checkpoints. Understanding how checkpoints are regulated is therefore important from the points of view of both tumorigenesis and cancer treatment. In this review, we present an overview of the molecular hierarchy of the checkpoint signaling network and the emerging role of checkpoint targets, especially checkpoint kinase 1, in cancer therapy. Further, we discuss the results of recent clinical trials involving the nonspecific checkpoint kinase 1 inhibitor, UCN-01, and the challenges we face with this new therapeutic approach.

Original languageEnglish
Pages (from-to)1955-1960
Number of pages6
JournalClinical Cancer Research
Issue number7
StatePublished - 1 Apr 2007
Externally publishedYes


Dive into the research topics of 'Targeting checkpoint kinase 1 in cancer therapeutics'. Together they form a unique fingerprint.

Cite this